Moradi boosts reported AudioEye (AEYE) stake to 21.3% as CEO holder
Rhea-AI Filing Summary
AudioEye, Inc. received an updated ownership report showing that investor and Chief Executive Officer David Moradi beneficially owns 2,662,117 shares of common stock, or 21.30% of the company. Sero Capital LLC is reported as beneficially owning 1,949,607 shares, or 15.70% of the class.
These percentages are calculated against 12,418,617 AudioEye shares outstanding as of October 31, 2025, with Mr. Moradi’s figure also including 81,444 shares issuable within 60 days under derivative securities. The filing states these securities are not held to change or influence control of AudioEye.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What ownership stake in AudioEye (AEYE) does David Moradi report?
David Moradi reports beneficial ownership of 2,662,117 AudioEye shares, representing 21.30% of the common stock. This includes 81,444 shares issuable within 60 days from derivative securities, based on 12,418,617 shares outstanding as of October 31, 2025.
Does the Schedule 13G/A state an intent to influence control of AudioEye (AEYE)?
The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of AudioEye. It also notes they are not held in connection with transactions having that purpose, other than activities related to a nomination under Rule 14a-11.
What voting and dispositive powers are reported for Sero Capital LLC and David Moradi in AEYE?
Sero Capital LLC reports shared voting and dispositive power over 1,949,607 shares and no sole power. David Moradi reports sole voting and dispositive power over 2,662,117 shares and no shared power, reflecting their respective beneficial ownership structures.
What is the event date for this AudioEye (AEYE) Schedule 13G/A amendment?
The date of the event requiring this Schedule 13G/A amendment is listed as December 31, 2025. This date anchors when the reported ownership levels applied for regulatory reporting purposes under Section 13 of the Securities Exchange Act.